YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth pote…
(RTTNews) - Today's top biotech gainers include Advanced Biomed, which led the rally with a gain of more than 200% over the past week. Novocure climbed following strong Q2 results and a revised full-year revenue outlook, while Medpace gain…
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list. TheFly reported on June 22 that H.C. Wainwright initiated c…
(RTTNews) - Today's top gainers include Universe Pharma, which expanded its pharmaceutical patent portfolio; Decoy Therapeutics, following the announcement of a PIPE financing; QuidelOrtho, on reports that it is exploring the sale of one o…
(RTTNews) - AgomAb Therapeutics NV (AGMB), a clinical-stage biopharmaceutical company, announced the study design of the Phase 2b NOV-ERA trial for Ontunisertib in the treatment of Fibrostenosing Crohn's Disease, aligned with the U.S. Food…
Is BAX a good stock to buy? We came across a bullish thesis on Baxter International Inc. on Heavy Moat Investments's Substack. In this article, we will summarize the bulls' thesis on BAX. Baxter International Inc.'s share was trading at $2…
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the follow…
(RTTNews) - Agomab Therapeutics NV (AGMB), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year ended December 31, 2025, and provided updates for the milestones ahead…
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and…
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,2…
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U…
AgomAb Therapeutics N.V. ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunol…
Agomab (AGMB) priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. JPMorgan, Morgan Stanley, Leerink and Kempen are acting as joint book running managers for the offering. Agomab is a clinical-stage biopharmaceutical compa…
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory dise…